Development and regulation of monoclonal antibody products: Challenges and opportunities

Abstract

An increasing number of monoclonal antibodies for cancer diagnosis and treatment are in clinical use and in the development pipeline, with more expected as new molecular targets are identified. As with all drugs, product quality, an appropriate pre-clinical pharmacology-toxicology testing program, and well-designed clinical trials are essential for a successful drug development program. However, protein products such as monoclonal antibodies present unique regulatory concerns. The derivation from biological sources as well as the constantly evolving technologies utilized to develop these products demands continuous appraisal of safety concerns, even while the accumulated experience with these protein products has facilitated their safety evaluations. Because of the complex nature of these products and their inherent heterogeneity, a mechanistic understanding of the mode of action along with careful attention to product design and manufacture are critical to assuring a safe, effective and consistent product. Protein products may be highly species specific, thus pharmacologically relevant animal models are an important component in accurately assessing pre-clinical safety and establishing initial dosing. Furthermore, the immunogenicity of protein products can impact its safety profile, dose exposure, and efficacy. Mechanistic insight should form the basis of biological assays used for monitoring efficacy, safety, lot-to-lot consistency and manufacturing changes. The inherent uniqueness of each product necessitates a flexible case-by-case approach for biologics review that is based on a strong scientific understanding of relative risks. This review will provide an overview of approaches used in the development of antibody-based cancer therapeutics and the scientific basis of regulatory reviews.

Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology

“…The conjugation of Abs on a nanosized carrier therefore results in very effective clearance from the blood [245, 246]. Removing the Fc fragment ( i.e.…”

Society of Toxicologic Pathology Position Paper on Best Practices on Recovery Studies

“…Although preclinical toxicities associated with most biologics are often a result of exaggerated intended pharmacological activity or inherent immunogenicity (Baldrick 2011;Sparrow et al 2011;Tabrizi et al 2009;Weinberg et al 2005), nonspecific effects can occur (Sparrow et al 2011). Some biopharmaceuticals (e.g., monoclonal antibodies) have lengthy half-lives resulting in continued exposure following the end of the dosing period (Dong et al 2011;Lobo, Hansen, and Balthasar 2004).…”

Biofunctionalized targeted nanoparticles for therapeutic applications

“…Monoclonal antibodies are large, complex molecules that require significant engineering at the molecular level to be effective [32, 33]. They are expensive to manufacture and there exists variation from batch to batch, limiting their efficiency as targeting molecules.…”